NEW YORK, Feb. 10 /PRNewswire/ -- Patients with non-Hodgkin’s lymphoma, any cancer of the lymphoid tissue in which lymphocytes proliferate and grow uncontrollably, now have a new weapon in the battle against an aggressive form of the disease. The US Food and Drug Administration has approved Rituxan for use in the first-line treatment of patients with diffuse large B-cell CD20-positive, non-Hodgkin’s lymphoma (DLBCL), in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or other anthracycline-based chemotherapy regimens.
With this approval, Rituxan in combination with chemotherapy becomes the first FDA-approved treatment to improve survival for patients with this type of Non-Hodgkin’s Lymphoma since the introduction of a specific kind of chemotherapy called CHOP more than 25 years ago.
An estimated 360,000 Americans have NHL and more than 58,000 new cases are diagnosed annually.
SATELLITE FEEDS: Friday February 10th, 2006 Monday, February 13th, 2006 6:30 PM - 6:45 PM ET 10:00AM - 10:15 AM ET IA 6 IA 6 Transponder 16 Transponder 16 C-Band C-Band Downlink Freq: 4020 Horizontal Downlink Freq: 4020 Horizontal Monday February 13th, 2006 1:00 PM - 1:15 PM ET IA 6 Transponder 15 C-Band Downlink Freq: 4000 Vertical Preview and access this video on Pathfire DMG: 23353 Search within the PR Newswire or MultiVu section by story ID # 23353 or by headline For technical assistance call Pathfire Customer Care at 1-888-345-0489 or e-mail support@pathfire.com
NEWS: FDA Approves Rituxan(R) for Diffuse Large B-Cell Lymphoma: An Aggressive Form of Non-Hodgkin’s Lymphoma
FORMAT: BRoll Package With Soundbites
ADDITIONAL RESOURCES: Video, contact information and more available at http://www.prnewswire.com/broadcast/23353/consumer.shtml
SOUNDBITES: -- Sandra J. Horning, M.D., Chair, Eastern Cooperative Oncology Group -- Michael Picarella, Patient
B-ROLL INCLUDES: ***Manufacturing Footage***Doctor Patient Footage***Patient Lifestyle***
VIDEO PROVIDED BY: Genentech Inc.
Video: http://www.prnewswire.com/broadcast/23353/press.shtmlGenentech Inc.
CONTACT: For technical information or hard copy, please call: MultiVuMedia Relations, 1-800-653-5313 ext. 3
